SCRI at Mary Crowley
Expanding Patient Access to Latest Therapies for People Facing Cancer in North Texas
Expanding Patient Access to Latest Therapies for People Facing Cancer in North Texas
Mary Crowley Cancer Research, an early phase clinical research center in Dallas, is now a part of the Sarah Cannon Research Institute (SCRI) family. Under the new banner, SCRI at Mary Crowley, patients will experience the same compassionate, personalized care – now with even greater access to cutting-edge therapies including an expanded clinical trial menu, strengthened research capabilities for on-site study operations
and access to a personalized medicine platform, Genospace, which transforms patient data into actionable insights for treatment.
SCRI at Mary Crowley will continue to be supported by locally trusted and globally recognized Texas Oncology physicians. Together, we look forward to making a greater impact in communities across North Texas.
SCRI at Mary Crowley
7777 Forest Lane,
Building C-707
Dallas, TX 75230
SCRI at Mary Crowley will continue to be supported by locally trusted and globally recognized Texas Oncology physicians. Together, we look forward to making a greater impact in communities across North Texas.
To view our full SCRI clinical trial offering, explore our clinical trial finder.